Thirty years of Alzheimer's disease genetics: the implications of systematic meta-analyses
The DOI matches its Crossref record; 113 of the 113 references it cites were found in a registry or an index.
Abstract
The genetic underpinnings of Alzheimer's disease (AD) remain largely elusive despite early successes in identifying three genes that cause early-onset familial AD (those that encode amyloid precursor protein (APP) and the presenilins (PSEN1 and PSEN2)), and one genetic risk factor for late-onset AD (the gene that encodes apolipoprotein E (APOE)). A large number of studies that aimed to help uncover the remaining disease-related loci have been published in recent decades, collectively proposing or refuting the involvement of over 500 different gene candidates. Systematic meta-analyses of these studies currently highlight more than 20 loci that have modest but significant effects on AD risk. This Review discusses the putative pathogenetic roles and common biochemical pathways of some of the most genetically and biologically compelling of these potential AD risk factors.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The ε4 allele of the apolipoprotein E (APOE) gene is the major genetic risk factor for AD and dementia with Lewy bodies (DLB) (1, 5, 6), whereas APOE2, a well-established longevity determinant, affords protection against the disease (7, 8).”
From APOE3 -Jacksonville (V236E) variant reduces self-aggregation and risk of dementia (2021) · cites this paper as [1]
In the citing paper
“Familial Alzheimer’s disease, which has an autosomal dominant form of inheritance and early onset, has been associated with mutations in APP, PSEN1 and PSEN2, three genes that are critical for beta amyloid (Aβ) production61.”
From Dendritic spine pathology in neuropsychiatric disorders (2011) · cites this paper as [61]
Citations
Cites
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
Goate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., et al. (1991) · Nature · doi:10.1038/349704a0 · Cited by 4,659
Strittmatter, W. J., Saunders, A. M., Schmechel, D., Pericak-Vance, M., Enghild, J., Salvesen, G. S., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.5.1977 · Cited by 4,268
Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease
Sherrington, R., Rogaev, E. I., Liang, Y., Rogaeva, E. A., Levesque, G., Ikeda, M., Chi, H., Lin, C., Li, G., Holman, K., et al. (1995) · Nature · doi:10.1038/375754a0 · Cited by 4,051
Self-citationAssociation of apolipoprotein E allele ϵ4 with late‐onset familial and sporadic Alzheimer's disease
Saunders, A. M., Strittmatter, W. J., Schmechel, D., St. George-Hyslop, P. H., Pericak-Vance, M. A., Joo, S. H., Rosi, B. L., Gusella, J. F., Crapper-MacLachlan, D. R., Alberts, M. J., et al. (1993) · Neurology · doi:10.1212/wnl.43.8.1467 · Cited by 3,786
Genome-wide association studies for complex traits: consensus, uncertainty and challenges
McCarthy, M. I., Abecasis, G. R., Cardon, L. R., Goldstein, D. B., Little, J., Ioannidis, J. P. A., & Hirschhorn, J. N. (2008) · Nature Reviews Genetics · doi:10.1038/nrg2344 · Cited by 2,891
Candidate gene for the chromosome 1 familial Alzheimer’s disease locus
Levy-Lahad, E., Wasco, W., Poorkaj, P., Romano, D. M., Oshima, J., Pettingell, W. H., Yu, C.-E., Jondro, P. D., Schmidt, S. D., Wang, K., et al. (1995) · Science · doi:10.1126/science.7638622 · Cited by 2,577
Self-citationTau-mediated neurodegeneration in Alzheimer’s disease and related disorders
Ballatore, C., Lee, V. M.-Y., & Trojanowski, J. Q. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2194 · Cited by 2,174 · cited 1×
“Despite the lack of MAPT mutations in AD, it is likely that tau dysfunction still contributes to AD ris”
BackgroundRogaev, E. I., Sherrington, R., Rogaeva, E. A., Levesque, G., Ikeda, M., Liang, Y., Chi, H., Lin, C., Holman, K., Tsuda, T., et al. (1995) · Nature · doi:10.1038/376775a0 · Cited by 2,052
Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database
Bertram, L., McQueen, M. B., Mullin, K., Blacker, D., & Tanzi, R. E. (2007) · Nature Genetics · doi:10.1038/ng1934 · Cited by 1,857 · cited 1×
“, none of these candidates has been proved to consistently influence disease risk or onset age in more than a handful of sample”
BackgroundSelf-citation
Research works printed but not linked: 1
- Meyer, J. M. & Breitner, J. C. Multiple threshold model for the onset of Alzheimer's disease in the NAS-NRC twin panel. Am. J. Med. Genet. 81, 92–97 (1998). · DOI · Paper page
Cited by
Items 501–600 of 754
Wang, Z.-T., Zhong, X.-L., Tan, M., Wang, H.-F., Tan, C., Zhang, W., Zheng, Z.-J., Kong, L., Tan, L., & Sun, L. J. (2018) · Annals of Translational Medicine · doi:10.21037/atm.2018.04.31 · Cited by 9
“Presenilin 1 (PSEN1), presenilin 2 (PSEN2), and amyloid precursor protein (APP) gene mutations bear responsibility for most familial AD cases (4).”
BackgroundGraf, A., Risson, V., Gustavsson, A., Bezlyak, V., Caputo, A., Tariot, P., Langbaum, J., Lopez-Lopez, C., & Viglietta, V. (2018) · The journal of prevention of Alzheimer's disease · doi:10.14283/jpad.2018.49 · Cited by 9
“Subjects with apolipoprotein E ε4 allele (APOE4) are at a higher risk of developing AD and possibly an earlier onset of the disease due to enhance amyloid-β deposition (5-8).”
BackgroundRisk Factors for Severe COVID-19 and Hepatitis C Infections: The Dual Role of Apolipoprotein E4
Lima, F. B., Bezerra, K. C., Nascimento, J. C. R., Meneses, G. C., & Oriá, R. B. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.721793 · Cited by 8
“ApoE is a 299amino acid protein that binds to plasma lipoproteins and serves as a cholesterol carrier for liver metabolization (12, 13).”
BackgroundRamos, A. A., Galiano‐Castillo, N., & Machado, L. (2022) · Neuropsychology Review · doi:10.1007/s11065-022-09555-2 · Cited by 11
“…to exclude studies included first-degree relatives of individuals with autosomal dominantly inherited familial AD, also known as early-onset AD (Bertram & Tanzi, 2008), first-degree relatives of individuals with non-LOAD dementia type (e.g., frontotemporal dementia), lack of required…”
BackgroundShen, H., He, Z., Pei, H., Zhai, L., Guan, Q., & Wang, G. (2022) · Phytotherapy Research · doi:10.1002/ptr.7597 · Cited by 9
“Alzheimer's disease (AD) is a kind of central nervous system (CNS) degenerative disease (Ringman et al., 2005) with the pathological bases of selective damage of brain tissue (Bertram & Tanzi, 2008), amyloid deposition and neurofibrillary tangles.”
BackgroundChukwu, L. C., Ekenjoku, J. A., Ohadoma, S. C., Olisa, C. L., Okam, P. C., Okany, C. C., Ramalam, M. A., & Innocent, O. C. (2023) · World Journal of Advanced Research and Reviews · doi:10.30574/wjarr.2023.17.2.20200335 · Cited by 10
“A number of genetic risk factors for AD have been proposed (Warging and Rosenberg, 2008; Bertram and Tanzi 2008; Harold, et al 2009; Lambert, et al 2009).”
Özge, A., Ghouri, R., Öksüz, N., & Taşdelen, B. (2023) · Frontiers in Neurology · doi:10.3389/fneur.2023.1239995 · Cited by 11
“A positive family history of dementia, particularly in first-degree relatives, is a well-established risk factor for both the development and rapid cognitive decline of Alzheimer’s disease progression (41).”
BackgroundPandey, J. P. (2009) · Journal of Alzheimer s Disease · doi:10.3233/jad-2009-1094 · Cited by 12
“…association and linkage studies have reported hundreds of putative susceptibility genes for Alzheimer’s disease (AD), but the majority of these claims – with the exception of the ε 4 allele of the apolipoprotein E (APOE) gene – have not been consistently replicated in subsequent studies [1].”
Gavín, R., Ferrer, I., & del Río, J. A. (2009) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.10.010 · Cited by 12
“…between polymorphism at codon 129 and the pathological and clinical features of AD (see Hooper and Turner, 2008; Poleggi et al., 2008 for reviews) although a systematic meta-analysis of AD genetic association studies revealed PRNP as a susceptible gene (see Bertram and Tanzi, 2008 for review).”
Jilani, M. S., Tagwireyi, D., Gadaga, L. L., Maponga, C. C., & Mutsimhu, C. (2018) · Behavioural Neurology · doi:10.1155/2018/2057219 · Cited by 11
“Oxidative stress also appears to be a major cause of AD-related pathologies caused by oxidative reactive species [5].”
BackgroundShi, J., Zhang, X., Ni, J., Wei, M., Li, T., Zhou, B., Liu, X., Zhang, L., Wang, P., Tian, J., et al. (2018) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1016/j.trci.2018.10.008 · Cited by 9
“This transgenic mouse model harbors APP and PS1 gene mutations and offer a powerful animal model with markedly Ab burden to study the Ab pathogenesis of AD and to explore the new therapeutic strategy for this disease [36].”
BackgroundNatural Modulators of Amyloid-Beta Precursor Protein Processing.
Zhang, C., & Tanzi, R. E. (2012) · PubMed · Cited by 11
Self-citationNeurobiology of Alzheimer’s Disease
Wong, P. C., Savonenko, A. V., Li, T., & Price, D. L. (2012) · Elsevier eBooks · doi:10.1016/b978-0-12-374947-5.00046-8 · Cited by 12
Wang, X., Cui, N., Gao, J.-J., Qiu, X., Yang, N., & Zheng, F. (2014) · Journal of Neural Transmission · doi:10.1007/s00702-014-1235-x · Cited by 8
“…factors (Bertram et al. 2007), the e4 allele of the apolipoprotein E gene (APOE e4) is the only well-confirmed genetic risk factor associated with SAD (Genin et al. 2011); however, the presence of APOE e4 allele is neither necessary nor sufficient for SAD development (Bertram and Tanzi 2008).”
BackgroundArzouni, N., Matloff, W. J., Zhao, L., Ning, K., & Toga, A. W. (2020) · PubMed · Cited by 12
Robinson, M. J., Newbury, S., Singh, K., Leonenko, Z., & Beazely, M. A. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-230753 · Cited by 8
“The production of A (cid:2) from the amyloid-(cid:2) protein precursor (A (cid:2) PP) occurs at and depends on the lipid membrane as it is initiated by membrane-associated enzymes, (cid:2) - and (cid:4) -secretases [4, 7].”
BackgroundLiu, Q., Miao, D., Yu, J., Xing, Y.-Y., Zhong, X.-L., Wu, Z., Zhang, Q., & Tan, L. (2012) · Neuroscience Letters · doi:10.1016/j.neulet.2012.02.030 · Cited by 9
Combination Drug Therapy for the Treatment of Alzheimer’s Disease
Alvarez, X. A., Linares, C., & Masliah, E. (2012) · European Neurological Review · doi:10.17925/enr.2012.07.02.92 · Cited by 9
Liu, J., Men, Y., Li, J., Men, Z., Peng, S., Sun, H., & Li, Z. (2022) · Advanced Materials Interfaces · doi:10.1002/admi.202102263 · Cited by 8
He, C.-Y., Wang, Z.-T., Shen, Y., Shi, A., Li, H., Chen, D., Zeng, G., Tan, C., Yu, J., Zeng, F., et al. (2022) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.13965 · Cited by 8
“, severe Parkinson's disease); (3) severe cardiac, pulmonary, hepatic, renal diseases or any kind of tumor; (4) declined to participate in the study.”
Wang, C., Wang, K., & Wang, Z. (2014) · Analytica Chimica Acta · doi:10.1016/j.aca.2014.12.006 · Cited by 8
Chen, L., Wan, L., Zhang, L., Wang, H., He, W., Tai, J., Li, X., & Li, X. (2011) · PLoS ONE · doi:10.1371/journal.pone.0024495 · Cited by 8
“the Alzheimer’s disease pathway, have been determined from experiments [9,10].”
MethodMagini, A., Urbanelli, L., Ciccarone, V. A., Tancini, B., Polidoro, M., Timperio, A. M., Zolla, L., Tedde, A., Sorbi, S., & Emiliani, C. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-091522 · Cited by 9
“Mutations in either the A β PP gene or presenilin genes have been described in a modest number of patients with familial early-onset AD (FAD) [9],but the majority of late-onset or sporadic AD (SAD) cases are not genetically transmitted and their pathogenesis remains unknown.”
NME8 rs2718058 polymorphism with Alzheimer's disease risk: a replication and meta-analysis
Liu, S., Wang, X.-C., Tan, M., Wang, H.-F., Zhang, W., Wang, Z.-X., Yu, J., & Tan, L. (2016) · Oncotarget · doi:10.18632/oncotarget.9086 · Cited by 9
“By far, only the ε4 allele of the apolipoprotein E (APOE) gene has been identified to relate with the risk of the more common LOAD [2].”
BackgroundBiomarkers for Alzheimer’s Disease
Farooqui, A. A. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-809937-7.00007-0 · Cited by 9
Repeat length variations in ATXN1 and AR modify disease expression in Alzheimer's disease
Gardiner, S. L., Harder, A. V. E., Campman, Y. J. M., Trompet, S., Gussekloo, J., van Belzen, M. J., Boogaard, M. W., Roos, R. A. C., Jansen, I. E., Pijnenburg, Y. A. L., et al. (2018) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2018.09.007 · Cited by 10
Neurodegeneration: Paying It Off with Sleep
Keene, A. C., & Joiner, W. J. (2015) · Current Biology · doi:10.1016/j.cub.2015.02.003 · Cited by 10
Horáková, D., Kýr, M., Havrdová, E., Doležal, O., Lelková, P., Pospíšilová, L., Bergsland, N., Dwyer, M. G., Cox, J. L., Hussein, S. M., et al. (2010) · Folia Biologica · doi:10.14712/fb2010056060242 · Cited by 10
Cai, Y., Fan, Y., Wu, W., & Chen, W. (2025) · Frontiers in Physiology · doi:10.3389/fphys.2025.1508661 · Cited by 9
CME ARTICLE Updated guidelines for the diagnosis of Alzheimer disease: A clinical review
Grandy, J. K. (2012) · JAAPA · doi:10.1097/01720610-201204000-00010 · Cited by 7
PRS-Net: Interpretable Polygenic Risk Scores via Geometric Learning
Li, H., Zeng, J., Snyder, M. P., & Zhang, S. (2024) · Lecture notes in computer science · doi:10.1007/978-1-0716-3989-4_35 · Cited by 8
Triaca, V. (2013) · Adipobiology · doi:10.14748/adipo.v5.292 · Cited by 8
“There are two forms of AD: (i) the genetic early onset familiar AD (FAD), with mutations in the amyloid precursor protein (APP) presenilin (PS1 and PS2) genes, and (ii) the age-related, sporadic and late onset AD (LOAD), representing 90 % of AD cases (1).”
BackgroundHow close is the stem cell cure to the Alzheimer's disease: Future and beyond?
Tang, J. (2012) · PubMed Central · doi:10.3969/j.issn.1673-5374.2012.01.011 · Cited by 12
“%) of AD patients are sporadic populations (sAD) while 5-10% patients are diagnosed as having early-onset AD, half of whom are familiar AD (fAD). fAD is caused by a mutation in at least one of three genes: presenilin 1/2 and amyloid precursor protein (APP) [32] .”
BackgroundRad, F. R., Akbari, M. G., Zamani, M., Bayat, S., & Zamani, M. (2021) · Molecular Neurobiology · doi:10.1007/s12035-021-02295-z · Cited by 7
Apolipoprotein E polymorphisms status in Iranian patients with multiple sclerosis
Rafiei, M., Yeganeh, M. Z., Sheikholeslami, S., Gozalpour, E., Ghaffarpour, M., & Hedayati, M. (2012) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2012.05.050 · Cited by 9
“Thirty years of Alzheimer's disease genetics: the implications of systematic meta-analyses.”
BackgroundInfluentialGene and Genome Sequencing: Interpreting Genetic Variation at the Nucleotide Level
Wyandt, H. E., Wilson, G. N., & Tonk, V. S. (2017) · Springer eBooks · doi:10.1007/978-981-10-3035-2_11 · Cited by 7
Small molecule biomarkers in Alzheimer’s disease
Kim, M. G., & Legido‐Quigley, C. (2018) · OCL · doi:10.1051/ocl/2018027 · Cited by 8
“…1994; Foley, 2010), but this hypothesis has been gaining acceptability only in recent years (Proitsi et al., 2014; Djelti et al., 2015), after the discovery of e4 allele of the apolipoprotein E (ApoE) gene being the strongest LOAD genetic risk factor (Corder et al., 1993; Bertram and Tanzi, 2008).”
BackgroundThe relationship between the minor allele content and Alzheimer's disease
Chen, H., Lei, X., Yuan, D., & Huang, S. (2020) · Genomics · doi:10.1016/j.ygeno.2020.01.015 · Cited by 7
Laminin-database v.2.0: an update on laminins in health and neuromuscular disorders
Golbert, D. C. F., Santana-Van-Vliet, E., Mundstein, A. S., Calfo, V., Savino, W., & de Vasconcelos, A. T. R. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt901 · Cited by 7
Neurochemical Aspects of Neurological Disorders
Farooqui, A. A. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-815461-8.00001-3 · Cited by 12
Potential protection from Alzheimer’s disease by wheat germ and rice bran nano-form in rat model
Yaseen, A. A., Al‐Okbi, S. Y., Hussein, A., Mohamed, D. A., Mohammad, A. A., Fouda, K. A., & Mehaya, F. M. (2019) · Journal of Applied Pharmaceutical Science · doi:10.7324/japs.2019.s108 · Cited by 11
“…disease is amongst the most common neurodegenerative disorders characterized by dementia with affected behavior and cognitive function in elderly and represents a major medical and social burden in both developed and developing countries (Bertram and Tanzi, 2008; Brookmeyer et al., 2007).”
BackgroundSingh, K., Gupta, J. K., Sethi, P., Mathew, S., Bhatt, A., Sharma, M. C., Saha, S., Khan, S., & Kumar, S. (2024) · Current Topics in Medicinal Chemistry · doi:10.2174/0115680266305736240725052825 · Cited by 21
Luo, X., Zhu, J., Cheng, Z., Zhang, F., Zhang, G., Yuan, J., & Jin, C. (2014) · International Journal of Neuroscience · doi:10.3109/00207454.2014.944616 · Cited by 6
“To date, the ε4 allele of the apolipoprotein E gene (APOE ε4) is the only well-established susceptibility gene for SAD, but it is not necessary or sufficient for the development of AD [6,7].”
BackgroundTranscriptomic Heterogeneity of Alzheimer’s Disease Associated with Lipid Genetic Risk
Miao, X., Liu, W., Fan, B., & Lin, H. (2020) · NeuroMolecular Medicine · doi:10.1007/s12017-020-08610-6 · Cited by 6
“1993; Bertram and Tanzi 2008).”
BackgroundInflammation-Mediated Responses in the Development of Neurodegenerative Diseases
Nainu, F., Mamada, S. S., Harapan, H., & Emran, T. B. (2023) · Advances in experimental medicine and biology · doi:10.1007/978-981-19-7376-5_3 · Cited by 6
Kucikova, L., Zeng, J., Muñoz‐Neira, C., Terrera, G. M., Huang, W., Gregory, S., Ritchie, C. W., O'Brien, J. T., & Su, L. (2023) · Journal of Neurology · doi:10.1007/s00415-023-11809-9 · Cited by 6
“These genes were selected as APOEe4 is consistently reported as a high-risk factor for AD [13], and MAPT is involved in tau production, which is aberrantly aggregated in AD and related tauopathies [14].”
BackgroundThe Use of Biomarkers for Prediction and Prevention of Alzheimer’s and Parkinson’s Diseases
Mandel, S. A., & Korczyn, A. D. (2012) · Advances in predictive, preventive and personalised medicine · doi:10.1007/978-94-007-5866-7_6 · Cited by 7
“Detection of the mutations in these genes can identify at-risk family members, but it is not generalizable to sporadic AD [25, 26].”
BackgroundChen, B. J., Mills, J. D., Janitz, C., & Janitz, M. (2015) · Methods in molecular biology · doi:10.1007/978-1-4939-2627-5_20 · Cited by 6
The Genetic Basis of Alzheimer’s Disease
Hooli, B. V., & Tanzi, R. E. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802173-6.00002-2 · Cited by 6
Self-citationDelayed amyloid plaque deposition and behavioral deficits in outcrossed AβPP/PS1 mice
Couch, B. A., Kerrisk, M. E., Kaufman, A. C., Nygaard, H. B., Strittmatter, S. M., & Koleske, A. J. (2012) · The Journal of Comparative Neurology · doi:10.1002/cne.23239 · Cited by 9
“Mutations in the genes encoding amyloid-b precursor protein (AbPP) or proteins involved in AbPP processing, such as presenilin-1 (PS1) and presenilin-2 (PS2), have been implicated as causal factors in familial AD (Bertram and Tanzi, 2008).”
BackgroundOmega-3 Fatty Acids and Cognitive Behavior
Giles, G. E., Mahoney, C. R., & Kanarek, R. B. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-410527-0.00025-9 · Cited by 6
SIGEL: a context-aware genomic representation learning framework for spatial genomics analysis
Li, W., Zhu, M., Xu, Y., Huang, M., Wang, Z., Chen, J., Wu, H., & Sun, X. (2025) · Genome biology · doi:10.1186/s13059-025-03748-7 · Cited by 15
Atanasova, M. (2025) · Pharmaceuticals · doi:10.3390/ph18101457 · Cited by 5
Fattahi, F., Asadi, M., Abed, S., Kouchakali, G., Kazemi, M., Derakhshan, S. M., & Khaniani, M. S. (2024) · Metabolic Brain Disease · doi:10.1007/s11011-024-01431-7 · Cited by 7
“Three genes have been found to exhibit autosomal dominant mutations: presenilin 1 (PSEN1), presenilin 2 (PSEN2), and APP (Bertram and Tanzi 2008).”
InfluentialDonev, R., & Howell, O. W. (2012) · Advances in protein chemistry and structural biology · doi:10.1016/b978-0-12-394287-6.00004-5 · Cited by 5
Huang, R., Tian, S., Cai, R., Sun, J. L., Xia, W., Dong, X., Shen, Y., & Wang, S. (2017) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.13079 · Cited by 5
“Although the processes of AD could be triggered by many environmental factors, previous studies also suggested that genetic polymorphisms play an important role in AD, among which mutations in amyloid precursor protein (APP), presenilin-1 (PSEN1), presenilin-2 (PSEN2) and apolipoprotein E (APOE) have been proved to be…”
BackgroundTownley, R. A., Polsinelli, A. J., Fields, J. A., Machulda, M. M., Jones, D. T., Graff‐Radford, J., Kantarci, K., Lowe, V. J., Rademakers, R., Baker, M. C., et al. (2020) · Neurocase · doi:10.1080/13554794.2020.1787458 · Cited by 5
“Familial inheritance makes up roughly 15% of known prion disease cases, which is consistent with described inheritance patterns of other disorders such as neurodegenerative diseases (Bertram & Tanzi, 2008; Minikel et al., 2016).”
BackgroundElectrochemical detection of AChE-induced gold nanostructure growth on disposable chips
Fiorella, D., Cheng, X. R., Chan, T., & Kerman, K. (2010) · Electrochemistry Communications · doi:10.1016/j.elecom.2010.12.010 · Cited by 5
Stem cell models of Alzheimer's disease and related neurological disorders
Livesey, F. J. (2012) · Alzheimer s Research & Therapy · doi:10.1186/alzrt147 · Cited by 6
“Familial AD makes up less than 1% of cases of AD, and disease-causing mutations either increase production of longer forms of Aβ peptides, particularly Aβ42, or increase the tendency of Aβ to form oligomers and fi brils [17,18].”
BackgroundZhao, W., Blue, E., Cheung, C. Y. K., Steinbart, E. J., Schellenberg, G. D., Bird, T. D., & Wijsman, E. M. (2013) · American Journal of Medical Genetics Part B Neuropsychiatric Genetics · doi:10.1002/ajmg.b.32133 · Cited by 7
“A number of rare mutations in three autosomal genes—amyloid precursor protein (APP [MIM 104760]) and the two presenilins (PSEN1 [MIM 104311] and PSEN2 [MIM 600759])—are causal in EOAD [Goate et al., 1991; Levy-Lahad et al., 1995; Sherrington et al., 1995; Bertram and Tanzi, 2008].”
BackgroundHarasta, A. E., & Ittner, L. M. (2017) · Advances in neurobiology · doi:10.1007/978-3-319-57193-5_1 · Cited by 6
Yin, J., Feng, W. Q., Yuan, H., Yuan, J., Wu, Y., Liu, X., Jin, C., & Cheng, Z. (2019) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s186705 · Cited by 5
Rattinger, G. B., Mullins, C. D., Zuckerman, I. H., Onukwugha, E., & Delisle, S. (2010) · The journal of nutrition health & aging · doi:10.1007/s12603-010-0315-3 · Cited by 5
“Our focus was on Alzheimer’s disease and related dementias (ADRD) associated with aging and older adults and we excluded those patients who potentially had early onset Alzheimer’s disease (5, 29-31 ).”
Differenzialdiagnose demenzieller Erkrankungen
Reith, W., & Mühl‐Benninghaus, R. (2015) · Der Radiologe · doi:10.1007/s00117-014-2799-z · Cited by 5
Neuroimaging of Alzheimer’s Disease, Mild Cognitive Impairment, and Other Dementias
Risacher, S. L., & Saykin, A. J. (2010) · Springer eBooks · doi:10.1007/978-1-4419-6373-4_19 · Cited by 5
MAMs and Mitochondrial Quality Control: Overview and Their Role in Alzheimer’s Disease
Luo, J.-S., Zhai, W.-H., Ding, L.-L., Zhang, X.-J., Han, J., Ning, J., Chen, X.-M., Jiang, W., Yan, R., & Chen, M. (2024) · Neurochemical Research · doi:10.1007/s11064-024-04205-w · Cited by 4
“FAD, which accounts for 1–6% of total AD cases, is associated with genetic factors [3].”
Stress Gene Deregulation in Alzheimer Peripheral Blood Mononuclear Cells
Maes, O. C., Chertkow, H. M., Wang, E., & Schipper, H. M. (2011) · Humana Press eBooks · doi:10.1007/978-1-60761-956-7_11 · Cited by 4
Metabolomics in the Study of Alzheimer's Disease
Ibáñez, C., Valdés, A., García‐Cañas, V., & Simó, C. (2014) · Comprehensive analytical chemistry · doi:10.1016/b978-0-444-62650-9.00010-5 · Cited by 6
GAB2 polymorphism rs2373115 confers susceptibility to sporadic Alzheimer's disease
Jin, C., Wu, C., Liu, X., Zhang, F., Tian, L., Yuan, J., Wang, G., & Cheng, Z. (2013) · Neuroscience Letters · doi:10.1016/j.neulet.2013.10.036 · Cited by 5
Ledo, A., Rocha, B. S., & Laranjinha, J. A. N. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-11488-6_10 · Cited by 5
Farlow, J. L., & Foroud, T. (2013) · Seminars in Neurology · doi:10.1055/s-0033-1359313 · Cited by 7
Jin, C., Zhang, F., Zhu, J., Yuan, J., Xia, M., Xu, Q. S., Jiang, X., Wu, Y., & Xu, W. (2012) · International Journal of Neuroscience · doi:10.3109/00207454.2012.751533 · Cited by 5
“com the ε4 allele of the apolipoprotein E gene (APOE) is the only well-established susceptibility gene for SAD, but it is neither necessary nor sufficient for AD [6, 7].”
BackgroundUnderstanding and Ameliorating the TTR Amyloidoses
Johnson, S. M., Wiseman, R. L., Paulsson, J. F., Choi, S., Powers, E. T., Buxbaum, J. N., & Kelly, J. W. (2010) · Wiley eBooks · doi:10.1002/9780470572702.ch45 · Cited by 5
Designing Novel Peptidic Inhibitors of Beta Amyloid Oligomerization
Roy, S. S. (2010) · Libraries and Cultural Resources (University of Calgary) · doi:10.5072/prism/17548 · Cited by 8
Jiraanont, P., Wang, J. Y., Durbin-Johnson, B., Hwang, Y. H., Hessl, D. R., Rivera, S. M., Hagerman, R. J., & Tassone, F. (2026) · Neurobiology of Disease · doi:10.1016/j.nbd.2026.107292 · Cited by 3
“The neutral Apo ε 3 is the most common allele in all ethnic groups (Bertram and Tanzi, 2008; Vemuri et al., 2010; Holtzman et al., 2012; Liu et al., 2013; Reiman et al., 2020).”
The APOE gene and cognitive function in non-demented and Alzheimer's disease patients
Payton, A. (2009) · Reviews in Clinical Gerontology · doi:10.1017/s0959259809990268 · Cited by 3
Amyloidopathy in the Eye of Alzheimer′s Disease
Zhang, X. (2011) · Journal of Addiction Research & Therapy · doi:10.4172/2155-6105.s5-005 · Cited by 3
“ISSN:2155-6105 JART, an open access journal Psychiatric Disorders: Alzheimer’s Disease J Addict Res Ther cases) [3,8,19], whereas 90-95% cases are late-onset AD [>65 years old] and a variant (ε4) of the gene encoding apolipoprotein E (APOE) has been associated with this disease type [20].”
BackgroundInfluentialDementia: Genes, Environments, Interactions
Gatz, M., Jang, J. Y., Karlsson, I., & Pedersen, N. L. (2013) · Springer eBooks · doi:10.1007/978-1-4614-7447-0_7 · Cited by 3
Li, A. (2013) · Hereditary Genetics · doi:10.4172/2161-1041.1000e105 · Cited by 3
Metaepidemiologie und Qualitätssicherung klinischer Evidenzproduktion
Haring, R. (2017) · Springer eBooks · doi:10.1007/978-3-662-55377-0_4 · Cited by 3
Human APOE ɛ3 and APOE ɛ4 Alleles Have Differential Effects on Mouse Olfactory Epithelium
Khan, N., Alimova, Y. V., Clark, S. J., Vekaria, H. J., Walsh, A. E., Williams, H. C., Hawk, G. S., Sullivan, P. G., Johnson, L. A., & McClintock, T. S. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-215152 · Cited by 6
“In the brain, ApoE is expressed primarily in astrocytes where it helps to carry cholesterol and other lipids to neurons to help them maintain cell membranes and synapses [13–17].”
Rahman, M. M., Sarker, M. T., Ahmed, S., Uddin, M. N., Islam, M. S., Islam, M. R., Das, S., Mukherjee, N., Hemeg, H. A., Rauf, A., et al. (2023) · Process Biochemistry · doi:10.1016/j.procbio.2023.07.007 · Cited by 4
Targeting angiogenesis, inflammation, and oxidative stress in Alzheimer's diseases
Bhandari, M., Tiwari, R. K., Chanda, S., & Bonde, G. V. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13587-3.00003-5 · Cited by 5
Canonical Fuzzy Modeling of Disease State
Ingabire, H. N., Gong, Z., & Chen, Y. (2024) · IEEE Transactions on Fuzzy Systems · doi:10.1109/tfuzz.2024.3372905 · Cited by 3
Qin, Y., Ai, D., Jordan, A. E., Guo, X., Li, T., Diao, S., Zhao, H., Liu, Y., Xue, Q., Wang, Y., et al. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.729782 · Cited by 4
“Other factors that may lead to sex differences are that the risk of AD in females with the apoE4 gene is three to four times higher than that in non-carriers; this risk in men with or without apoE4 gene is relatively low (Bertram and Tanzi, 2008).”
BackgroundS3-Leitlinie »Demenzen« — Kurzversion
Maier, W., Jessen, F., Schneider, F. W., Deuschl, G., Spottke, A. E., & Reichmann, H. (2010) · Springer eBooks · doi:10.1007/978-3-642-13092-2_3 · Cited by 4
The ABCA7 transporter, brain lipids and Alzheimer’s disease
Soscia, S. J., & Fitzgerald, M. L. (2013) · Clinical Lipidology · doi:10.2217/clp.12.91 · Cited by 4
JifangZhang, & YantuanLi (2013) · PubMed Central · doi:10.3969/j.issn.1673-5374.2013.08.010 · Cited by 3
“Alzheimer’s disease is a common age-associated progressive neurodegenerative disorder [1-2] .”
BackgroundGenetics of Vascular Dementia.
Murray, M. E., Meschia, J. F., Dickson, D. W., & Ross, O. A. (2010) · PubMed · Cited by 3
Drug Discovery Processes to Drug Targeting Mechanisms
Maqbool, F., Abid, A., & Ahmed, I. (2017) · International Journal of Pharmacology · doi:10.3923/ijp.2017.773.784 · Cited by 3
Tan, J., Zhang, X., Fang, J., Shen, H., Ding, X., & Zheng, G. (2021) · Journal of Chromatographic Science · doi:10.1093/chromsci/bmab115 · Cited by 3
Pathogenesis and Therapeutic Strategies in Alzheimer’s Disease: From Brain to Periphery
Yu, J., & Zhang, C. M. (2015) · Neurotoxicity Research · doi:10.1007/s12640-015-9576-2 · Cited by 4
“The leading theory of the disease is currently the amyloid cascade hypothesis, which posits that aberrant amyloid-beta (Ab) production or clearance in brain is an early component in the pathogenesis of AD (Bertram and Tanzi 2008; Hardy and Selkoe 2002).”
BackgroundGrabrucker, S., Marizzoni, M., Silajdžić, E., Lopizzo, N., Mombelli, E., Nicolas, S., Dohm-Hansen, S., Scassellati, C., Moretti, D. V., Rosa, M., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.11.04.515189 · Cited by 3
Chen, J., Han, X., Liu, Z., Zhou, C., Hu, R., Tabassam, S., Wyatt-Johnson, S. K., Oblak, A. L., Brutkiewicz, R. R., Lin, M., et al. (2026) · IEEE Transactions on Biomedical Engineering · doi:10.1109/tbme.2025.3614233 · Cited by 2
“AD is characterized by gradual and progressive nature rather than being an acute illness and is influenced by multiple risk factors such as genetic factors [4], cardiovascular factors [5], cerebrovascular dysfunction [6] etc.”
Accomplishment of Toxicity Prediction by CADD Tools
Kaushik, N., & Kumar, S. (2025) · Springer eBooks · doi:10.1007/978-981-96-4154-3_16 · Cited by 3
Shi, J., & Seltzer, B. (2011) · Neurodegenerative Disease Management · doi:10.2217/nmt.11.27 · Cited by 2
Regulated intramembrane proteolysis, innate immunity and therapeutic targets in Alzheimer’s disease
Hurst, T. P., Coleman-Vaughan, C., Patwal, I., & McCarthy, J. V. (2016) · AIMS molecular science · doi:10.3934/molsci.2016.2.138 · Cited by 2
“studies (GWAS) and more recent, exome and genome sequencing studies to identify common genetic variants associated with sporadic late-onset AD, reviewed elsewhere [8-10].”
Dendritic spine pathology in neuropsychiatric
Cahill, M. E., Jones, K. A., VanLeeuwen, J., & Woolfrey, K. M. (2011) · Cited by 2
review on the modern drug discovery process
Kumari, S., Singh, K., & Mukopadayay, S. (2022) · International Journal of Health Sciences · doi:10.53730/ijhs.v6ns6.10207 · Cited by 2
General Process for Rational Design and Discovery of MTDs
Wang, Z., & Yang, B. (2022) · Springer eBooks · doi:10.1007/978-3-031-04998-9_17 · Cited by 2
Metadata
- Authors
- Bertram, L., & Tanzi, R. E.
- Affiliations
- Harvard University (US)
- Massachusetts General Hospital (US)
- Corresponding author
- Bertram, Lars
- Venue
- Nature Reviews Neuroscience
- Published
- 2008-10
- Volume
- 9
- Issue
- 10
- Pages
- 768-778
- ISSN
- 1471-003X (ISSN-L)
- 1471-0048
- OpenAlex
- W2018342879
- Cited by
- 747
- References
- 113
- Citations by year
- 2026: 12 · 2025: 16 · 2024: 25 · 2023: 21 · 2022: 33 · 2021: 26 · 2020: 29 · 2019: 34 · 2018: 41 · 2017: 46 · 2016: 37 · 2015: 41 · 2014: 46 · 2013: 59 · 2012: 62
- FWCI
- 7.89
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature reviews. Neuroscience (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- National Institute on Aging (5R01-AG23667, R01AG023667)
- National Institute of Mental Health (5R37MH60009, R37MH060009)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Keywords
- Alzheimer's disease genetics, genetic risk factors, candidate genes, meta-analysis, amyloid precursor protein, presenilin 1, presenilin 2, apolipoprotein E, early-onset familial Alzheimer's disease, late-onset Alzheimer's disease, disease pathology, metabolic pathways
- MeSH terms
- Alzheimer Disease, Animals, Apolipoproteins E, Brain Chemistry, Humans, Mutation, Risk Factors, Meta-Analysis as Topic, Amyloid beta-Protein Precursor, Genetic Predisposition to Disease, Presenilins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.